Incyte

Incyte EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Incyte (INCY) as of Sep 26, 2026 is 14.98. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 198.63 — a change of -92.46% (lower).

EV/EBIT

14.98

YoY

-92.46%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Incyte is 2026 14.98 . EV/EBIT (Enterprise Value to EBIT) of Incyte was 2025 198.63 . It decreases by -92.46% lower compared to the previous year.

The Incyte EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
49.82 USD
Jan 1, 2020
-76.31 USD
Jan 1, 2021
34.35 USD
Jan 1, 2022
34.01 USD
Jan 1, 2023
30.70 USD
Jan 1, 2024
198.63 USD
Jan 1, 2025
14.98 USD
Jan 1, 2026 (e)
22.96 USD
The Incyte EV/EBIT history
YEAREV/EBITYoY
est22.96+53.23%
14.98-92.46%
198.63+546.99%
30.70-9.72%
34.01-0.99%
34.35-145.01%
-76.31-253.17%
49.82-68.00%
155.70-288.35%
-82.67-159.58%
138.76-65.07%
397.24-109.48%
-4,188.25+722.66%
-509.11+3,742.34%
-13.25-109.14%
144.94-1,972.61%
-7.74+235.06%
-2.31-76.78%
-9.95+55.96%
-6.38—
Access this data via the Eulerpool API

Incyte Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Incyte's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Incyte's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Incyte's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Incyte grows earnings faster than its peers.

Incyte Stock analysis

What does Incyte do? The Incyte Corporation is a global biotechnology company specializing in the research and development of drugs for the treatment of cancer and other serious diseases. Incyte was founded in 1991 in Delaware, USA, by Roy Whitfield, a biotech entrepreneur, with the aim of finding new approaches to drug discovery. The company initially focused on developing DNA sequencing technologies and building an extensive database for drug identification. Over the years, Incyte expanded its expertise in genomics research and collaborated with pharmaceutical companies to develop new medications. In 2002, Incyte entered into a strategic alliance with Eli Lilly and Company to jointly research drugs for cancer and other diseases. Today, Incyte offers a wide range of medications for the treatment of cancer, immune and inflammatory disorders, and rare genetic diseases. The company's business model is based on the discovery and development of new drugs, utilizing its strengths in genomics research and biomarker development to identify and develop targeted therapies. Incyte has also increasingly focused on the development of immunotherapies, particularly antibodies targeting cancer and other diseases by activating the immune system. The company has positioned itself as a leading provider of genetic tests for rare diseases in the United States, offering a broad range of diagnostic tests based on genetic mutations. Incyte is a rapidly growing company with a strong emphasis on innovation and research. It has a strong presence in the field of cancer therapy and is working to expand its expertise in immunology and genomics research. Incyte is considered a promising candidate for future growth and success in drug development in the biotech industry. Incyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Incyte stock

EV/EBIT (Enterprise Value to EBIT) of Incyte is 14.98 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Incyte changed from 198.63 to 14.98, representing a -92.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Incyte since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Incyte with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Incyte

All Key Metrics — Incyte